J. S. San Martin

发表

Effects of Teriparatide and Alendronate on Vertebral Strength as Assessed by Finite Element Modeling of QCT Scans in Women With Osteoporosis

T. Keaveny, D. Donley, Paul F. Hoffmann, 2006, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Digitized mammography: a clinical trial of postmenopausal women randomly assigned to receive raloxifene, estrogen, or placebo.

M. Freedman, S. Lo, J. Zeng, 2001, Journal of the National Cancer Institute.

Denosumab for prevention of fractures in postmenopausal women with osteoporosis.

Claus Christiansen, Cesar Libanati, Michael R McClung, 2009, The New England journal of medicine.

Effect of denosumab on bone mineral density and biochemical markers of bone turnover: six-year results of a phase 2 clinical trial.

J. S. San Martin, P. Miller, M. Peacock, 2011, The Journal of clinical endocrinology and metabolism.

Continued Beneficial Effects of Burosumab in Adults with X-Linked Hypophosphatemia: Results from a 24-Week Treatment Continuation Period After a 24-Week Double-Blind Placebo-Controlled Period

R. Eastell, J. S. San Martin, S. Ralston, 2019, Calcified Tissue International.

Comparison of the effect of raloxifene and continuous-combined hormone therapy on mammographic breast density and breast tenderness in postmenopausal women.

V. Jackson, J. S. San Martin, S. Carranza-Lira, 2003, American journal of obstetrics and gynecology.

Effect of raloxifene after recombinant teriparatide [hPTH(1–34)] treatment in postmenopausal women with osteoporosis

D. Felsenberg, G. Dalsky, J. S. San Martin, 2007, Osteoporosis International.

Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass.

J. S. San Martin, J. Gallagher, P. Miller, 2011, The Journal of clinical endocrinology and metabolism.

Efficacy and safety of burosumab in children aged 1-4 years with X-linked hypophosphataemia: a multicentre, open-label, phase 2 trial.

J. S. San Martin, M. Whyte, T. Carpenter, 2019, The lancet. Diabetes & endocrinology.

A Randomized, Double‐Blind, Placebo‐Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti‐FGF23 Antibody, in Adults With X‐Linked Hypophosphatemia: Week 24 Primary Analysis

J. S. San Martin, R. Lachmann, H. Cheong, 2018, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Volcanic activity accompanying the emplacement of dacitic lava domes and effusion of lava flows at Nevados de Chillán Volcanic Complex – Chilean Andes (2012 to 2020)

J. S. San Martin, O. Valderrama, J. Lazo, 2021, Journal of Volcanology and Geothermal Research.

Burosumab Improved Histomorphometric Measures of Osteomalacia in Adults with X‐Linked Hypophosphatemia: A Phase 3, Single‐Arm, International Trial

J. S. San Martin, F. Rauch, T. Kubota, 2019, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Burosumab Therapy in Children with X‐Linked Hypophosphatemia

J. S. San Martin, M. Whyte, A. Linglart, 2018, The New England journal of medicine.

RNAi inhibition of angiopoietin-like protein 3 (ANGPTL3) with ARO-ANG3 mimics the lipid and lipoprotein profile of familial combined hypolipidemia

S. Melquist, J. Knowles, P. Clifton, 2020 .

Growth Curves for Children with X-linked Hypophosphatemia

J. S. San Martin, A. Rogol, M. Whyte, 2019, The Journal of clinical endocrinology and metabolism.

Rickets severity predicts clinical outcomes in children with X-linked hypophosphatemia: Utility of the radiographic Rickets Severity Score.

J. S. San Martin, J. Pettifor, A. Creo, 2019, Bone.

Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk.

S. Cummings, O. Tørring, S. Boonen, 2011, The Journal of clinical endocrinology and metabolism.

The tactics of modern-day regulatory trials.

J. S. San Martin, N. Storm, Ricardo E. Dent-Acosta, 2012, The Journal of bone and joint surgery. American volume.

Comparison of the Effect of Denosumab and Alendronate on BMD and Biochemical Markers of Bone Turnover in Postmenopausal Women With Low Bone Mass: A Randomized, Blinded, Phase 3 Trial

Jacques P. Brown, D. Kiel, R. Recker, 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass.

G. Dalsky, D. Donley, J. S. San Martin, 2005, Archives of internal medicine.

Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial.

J. S. San Martin, P. Miller, M. McClung, 2008, Bone.

Effects of denosumab on bone histomorphometry: The FREEDOM and STAND studies

Jacques P. Brown, I. Reid, J. S. San Martin, 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.

J. S. San Martin, Huei Wang, D. Kendler, 2008, The Journal of clinical endocrinology and metabolism.

Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy

J. Kaufman, G. Dalsky, B. Mitlak, 2005, Osteoporosis International.

The Lifelong Impact of X-Linked Hypophosphatemia: Results From a Burden of Disease Survey

J. S. San Martin, C. Macica, A. Linglart, 2019, Journal of the Endocrine Society.

Bone remodeling in postmenopausal women who discontinued denosumab treatment: Off‐treatment biopsy study

Jacques P. Brown, A. Grauer, J. S. San Martin, 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Continued Beneficial Effects of Burosumab in Adults with X-Linked Hypophosphatemia: Results from a 24-Week Treatment Continuation Period After a 24-Week Double-Blind Placebo-Controlled Period

R. Eastell, J. S. San Martin, S. Ralston, 2019, Calcified Tissue International.

OR13-1 Burosumab Improves the Biochemical, Skeletal, and Clinical Symptoms of Tumor-Induced Osteomalacia Syndrome

R. Kumar, J. S. San Martin, P. Miller, 2019, Journal of the Endocrine Society.

Comparison of the Effect of Denosumab and Alendronate on BMD and Biochemical Markers of Bone Turnover in Postmenopausal Women With Low Bone Mass: A Randomized, Blinded, Phase 3 Trial

J. S. San Martin, B. Clarke, J. Álvaro-Gracia, 2009 .

Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass.

J. S. San Martin, P. Miller, L. Grazette, 2011, The Journal of clinical endocrinology and metabolism.